Fredun Pharmaceuticals Share Price

CMP as on19-Jan-21 14:12

₹ 403.95
3.95 0.99%

Open

₹ 410.00

Turnover (lac)

₹ 5

Prev. Close

₹ 400.00

Day's Vol (shares)

₹ 1,253

Day's Range

₹ 385.00
₹ 410.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 26-Oct-2020 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI Listing Regulations, 2015; we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, 9th November 2020 at 3:00 P.M. at the Registered Office of the Company interalia to discuss, consider and approve the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2020; We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Monday, 9th November, 2020 at 3:00pm; had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company and the Cash Flow Statement for the Second Quarter and Half Year ended 30th September, 2020; along with the Limited Review Report as issued by M/s. Savla & Associates; Statutory Auditors of the Company (As per BSE Announcement Dated on 09/11/2020)
Board Meeting - 03-Sep-2020 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/09/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI Listing Regulations, 2015; we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, September 15, 2020 at 3:00 P.M. at the Registered Office of the Company inter alia to discuss, consider and approve the Unaudited Financial Results of the Company for the first quarter and three months period ended June 30, 2020; We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Tuesday, September 15, 2020 ; had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the first quarter and three months ended June 30th, 2020; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 3:00 P.M. and concluded at 10:15PM. (As per BSE Announcement Dated on 15/9/2020)
Board Meeting - 23-Jul-2020 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2020 ,inter alia, to consider and approve 1. To discuss, consider and approve the Audited Financial Results of the Company for the Quarter and Year ended March 31st 2020 along with Audit Report of the Auditor thereon with Audited Balance Sheet, P & L A/c and Schedules &Notes. 2. To recommend Dividend if any, for the Financial Year ended March 31st 2020 - subject to the approval of the Shareholders at the ensuing AGM of the Company; 3. To discussa and approve drafts of Directors Report, Corporate Governance Report, Management Discussion & Analysis for the FY ended Mar 31st 2020 4. To discuss and approve appointment of Statutory Auditors and Secretarial Auditors for the Financial Year ended 2020-21. 5. To consider and approve reappointment of Managing Director Mr. Fredun Medhora and Whole Time Director Dr. (Mrs.) Daulat Medhora subject to approval of the shareholders at the ensuing AGM 6. To 7. To finalize Notice and Book Closure for the Annual General Meeting 8. Any other matter with the permission of the Chair 1. The Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2020; Statement of Assets and Liabilities and Cash Flow Statement, Profit & Loss A/c, Schedules and Notes along with the Auditors Report issued by M/s. Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Recommended Final Dividend @ 6.6% i.e., Rs. 0.66/- per Equity Share having face value of Rs. 10/- each for the Financial Year 2019-20; subject to the approval of the shareholders at the ensuing 33rd Annual General Meeting of the Company; Board of Directors has approved a dividend of Rs. 0.66per equity share for the financial year 31st March, 2020 subject to approval of shareholders at ensuing Annual General Meeting (AS Per BSE Announcement Dated on 29.07.2020)
Board Meeting - 31-Jan-2020 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI Listing Regulations, 2015; we wish to inform you that the 176th Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, February 12, 2020 at 3:30 P.M. at the Registered Office of the Company interalia to discuss, consider and approve the Unaudited Financial Results of the Company for the Quarter and nine months ended December 31, 2019. The Board Meeting to be held on 12/02/2020 has been revised to 12/02/2020 In compliance to Regulation 47 of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Notice of the ensuing Board Meeting of the Company scheduled to be held on Wednesday, February 12, 2020 at 3:30 P.M.; published in Business Standard & Mumbai Lakshadeep newspapers on February 1, 2020. (As Per BSE Announcement Dated on 01.02.2020) In compliance to Regulation 33 of SEBI Listing Regulations, 2015; we wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Wednesday, February 12, 2020; had considered and approved the Unaudited Financial Results of the Company for the Quarter and Nine months ended December 31, 2019; along with the Limited Review Report issued by M/s. Savla & Associates, Statutory Auditors of the Company; the copies of which are attached hereunder. Any other matter: 1. Approval of Appointment of Ms. Ankita Joshi (ACS43193) as Company Secretary cum Compliance Officer in compliance to the provisions of Section 203 of the Companies Act, 2013 and Rules made thereunder and Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (Annexure 1) (As Per BSE Announcement Dated 12.02.2020)